Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -70.00% |
| Return on Assets | -42.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.57 |
| Price-to-Book | 8.66 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -71.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $116.11M |
| Float | $113.28M |
| % Insiders | 2.79% |
| % Institutions | 64.43% |
Volatility is currently expanding
Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set.
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $39.97, moving 5.13% from the previous trading session.
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $37.48, denoting a -3.92% move from the preceding trading day.
Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current ~$5B valuation amid sector momentum. Novo Nordisk's oral Wegovy launch sets a new benchmark, highlighting peptide-based oral GLP-1 drugs' commercial potential and raising the value of VKTX's oral program. VKTX's injectable VK2735 faces intensified competition after Eli Lilly's Retatrutide Phase III results, which establish a higher efficacy standard (>24%).
NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.
Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the initiation of a Phase 1 single ascending dose (SAD) clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA). VK3019 is being developed as a potential treatment option for weight loss.
Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next?
